logo

For the Inventor, By the Inventor

Redwood City, CA, United States of America

Chris Allen Buhr

This inventor holds 11 USPTO granted patents and 5 published patent applications. Top assignees: Exelixis, Inc., Signal Pharmaceuticals, Inc.. Active years: 2005-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chris Allen Buhr. Retrieved from https://idiyas.com/inventor/chris-allen-buhr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 18.2

Average Co-Inventor Count = 9.1

ph-index = 7

Forward Citations = 147(Granted Patents)


Company Filing History:

goldMedal7 out of 177 
 
Exelixis, Inc.
 patents
silverMedal4 out of 169 
 
Signal Pharmaceuticals, Inc.
 patents

Years Active: 2005-2014

Loading Chart...
11 patents (USPTO):Explore Patents
1. 8710038 - Pyrazole kinase modulators and methods of use (2014-04-29),
2. 8648066 - Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture (2014-02-11),
3. 8247408 - Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer (2012-08-21),
4. 8101622 - Pyridopyrimidinone inhibitors of PI3Kα and mTOR (2012-01-24),
5. 8044062 - Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha (2011-10-25),
6. 8012956 - Tropane compounds (2011-09-06),
7. 7704995 - Protein kinase modulators and methods of use (2010-04-27),
8. 7220771 - Methods of using indazole derivatives as JNK inhibitors (2007-05-22),
9. 7211594 - Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith (2007-05-01),
10. 7208513 - Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith (2007-04-24),
11. 6897231 - Indazole derivatives as JNK inhibitors and compositions and methods related thereto (2005-05-24),

Title: Chris Allen Buhr: Innovator in Kinase Modulation

Introduction

Chris Allen Buhr is a prominent inventor based in Redwood City, CA (US). He has made significant contributions to the field of biochemistry, particularly in the development of compounds that modulate protein kinase activity. With a total of 11 patents to his name, Buhr's work has the potential to impact various medical treatments.

Latest Patents

Among his latest patents, Buhr has developed "Pyrazole kinase modulators and methods of use." This invention provides compounds that modulate protein kinase enzymatic activity, influencing cellular activities such as proliferation, differentiation, programmed cell death, migration, and chemoinvasion. The compounds are designed to inhibit, regulate, and/or modulate kinases, offering methods for treating kinase-dependent diseases and conditions. Another notable patent is for "Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture." This invention focuses on compounds of Formula I and their pharmaceutically acceptable salts or solvates, along with methods for making and using these compounds.

Career Highlights

Throughout his career, Chris Allen Buhr has worked with notable companies such as Exelixis, Inc. and Signal Pharmaceuticals, Inc. His experience in these organizations has allowed him to refine his expertise in drug development and biochemistry.

Collaborations

Buhr has collaborated with talented individuals in his field, including Sunghoon Ma and Tae-Gon Baik. These partnerships have contributed to the advancement of his research and innovations.

Conclusion

Chris Allen Buhr is a distinguished inventor whose work in kinase modulation holds promise for future medical advancements. His contributions to the field are marked by a series of innovative patents that address critical health challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…